An association of myeloproliferative neoplasms and obliterative portal venopathy.
作者信息
Mayer Jillian E, Schiano Thomas D, Fiel Maria Isabel, Hoffman Ronald, Mascarenhas John O
机构信息
Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1079, New York, NY, 10029, USA.
出版信息
Dig Dis Sci. 2014 Jul;59(7):1638-41. doi: 10.1007/s10620-013-3018-x. Epub 2014 Jan 29.
Abstract
摘要
相似文献
1
An association of myeloproliferative neoplasms and obliterative portal venopathy.骨髓增殖性肿瘤与闭塞性门静脉病的关联。
Dig Dis Sci. 2014 Jul;59(7):1638-41. doi: 10.1007/s10620-013-3018-x. Epub 2014 Jan 29.
2
Clinical predictors of outcome in MPN.骨髓增殖性肿瘤（MPN）结局的临床预测因素。
Hematol Oncol Clin North Am. 2012 Oct;26(5):1101-16. doi: 10.1016/j.hoc.2012.07.009. Epub 2012 Aug 28.
3
Leukemia and related disorders.白血病及相关疾病。
Hum Pathol. 1971 Dec;2(4):505-14. doi: 10.1016/s0046-8177(71)80054-0.
4
5
[Myeloproliferative disorders].[骨髓增殖性疾病]
Ther Umsch. 2004 Feb;61(2):131-42. doi: 10.1024/0040-5930.61.2.131.
6
7
Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy.肝硬化前期胆道疾病中的肝移植：门静脉高压常与结节性再生性增生和闭塞性门静脉病相关。
Am J Surg Pathol. 2006 Nov;30(11):1454-61. doi: 10.1097/01.pas.0000213286.65907.ea.
8
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.在瑞典11039例骨髓增殖性肿瘤患者的24577名一级亲属中，真性红细胞增多症、原发性血小板增多症和骨髓纤维化的风险增加。
Blood. 2008 Sep 15;112(6):2199-204. doi: 10.1182/blood-2008-03-143602. Epub 2008 May 1.
9
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?慢性炎症作为原发性血小板增多症、真性红细胞增多症和骨髓纤维化中突变的促进因素。一种人类炎症模型与癌症发展有关？
Leuk Res. 2013 Feb;37(2):214-20. doi: 10.1016/j.leukres.2012.10.020. Epub 2012 Nov 20.
10
引用本文的文献
1
A novel mutation associated with idiopathic portal hypertension: Case report and literature review.一种与特发性门静脉高压相关的新型突变：病例报告及文献综述。
ILIVER. 2022 Jul 14;1(2):90-95. doi: 10.1016/j.iliver.2022.06.001. eCollection 2022 Jun.
2
Obliteration of liver sinusoids through platelet aggregates associated to extramedullary haematopoiesis in myeloid neoplasms.在髓系肿瘤中，通过与髓外造血相关的血小板聚集体导致肝血窦闭塞。
Virchows Arch. 2025 Mar;486(3):491-497. doi: 10.1007/s00428-024-03844-2. Epub 2024 Jun 14.
3
Obliterative portal venopathy: A neglected and probably misdiagnosed disease with peculiar etiology in South America.闭塞性门静脉病：一种在南美洲病因特殊、被忽视且可能被误诊的疾病。
JGH Open. 2022 Nov 16;6(12):904-909. doi: 10.1002/jgh3.12840. eCollection 2022 Dec.
4
Modern management of splenomegaly in patients with myelofibrosis.骨髓纤维化患者脾肿大的现代治疗方法。
Ann Hematol. 2020 Jul;99(7):1441-1451. doi: 10.1007/s00277-020-04069-4. Epub 2020 May 17.
5
The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib.芦可替尼治疗的骨髓增殖性肿瘤患者肝脏活检结果的意义
Case Rep Hematol. 2019 Jan 6;2019:3294046. doi: 10.1155/2019/3294046. eCollection 2019.
本文引用的文献
1
Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms.门静脉血栓形成和骨髓增殖性肿瘤患者的长期随访。
J Thromb Haemost. 2011 Nov;9(11):2208-14. doi: 10.1111/j.1538-7836.2011.04484.x.
2
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.布加综合征患者肝内皮细胞中JAK2V617F突变的存在。
Blood. 2009 May 21;113(21):5246-9. doi: 10.1182/blood-2008-11-191544. Epub 2009 Mar 17.
3
Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.骨髓增殖性疾病中的血栓形成：患病率、预后因素以及白细胞和JAK2V617F的作用
Semin Thromb Hemost. 2007 Jun;33(4):313-20. doi: 10.1055/s-2007-976165.
4
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.JAK2 V617F突变常见于门静脉和肠系膜静脉血栓形成的患者中。
J Thromb Haemost. 2007 Jan;5(1):55-61. doi: 10.1111/j.1538-7836.2006.02277.x. Epub 2006 Oct 20.
5
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.人类骨髓增殖性疾病中酪氨酸激酶JAK2的获得性突变。
Lancet. 2005;365(9464):1054-61. doi: 10.1016/S0140-6736(05)71142-9.
6
Histopathology of portal hypertension: a practical guideline.门静脉高压症的组织病理学：实用指南。
Histopathology. 2003 Jan;42(1):2-13. doi: 10.1046/j.1365-2559.2003.01464.x.
7
Non-cirrhotic portal hypertension versus idiopathic portal hypertension.非肝硬化性门静脉高压症与特发性门静脉高压症
J Gastroenterol Hepatol. 2002 Dec;17 Suppl 3:S204-13. doi: 10.1046/j.1440-1746.17.s3.2.x.
8
Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients.西方特发性非肝硬化性肝内门静脉高压症：28例患者的重新评估
Gut. 2002 Aug;51(2):275-80. doi: 10.1136/gut.51.2.275.
9
Hepatoportal sclerosis.
Semin Liver Dis. 1995 Nov;15(4):329-39. doi: 10.1055/s-2007-1007285.
10
Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and extrahepatic portal vein obstruction.特发性门静脉高压症。与肝硬化门静脉高压症及肝外门静脉阻塞的比较。
Ann Intern Med. 1967 Jan;66(1):41-68. doi: 10.7326/0003-4819-66-1-41.
Zotero 插件